Literature DB >> 33882595

Drawing Reproducible Conclusions from Observational Clinical Data with OHDSI.

George Hripcsak1,2, Martijn J Schuemie2,3, David Madigan2,4, Patrick B Ryan1,2,3, Marc A Suchard2,5,6.   

Abstract

OBJECTIVE: The current observational research literature shows extensive publication bias and contradiction. The Observational Health Data Sciences and Informatics (OHDSI) initiative seeks to improve research reproducibility through open science.
METHODS: OHDSI has created an international federated data source of electronic health records and administrative claims that covers nearly 10% of the world's population. Using a common data model with a practical schema and extensive vocabulary mappings, data from around the world follow the identical format. OHDSI's research methods emphasize reproducibility, with a large-scale approach to addressing confounding using propensity score adjustment with extensive diagnostics; negative and positive control hypotheses to test for residual systematic error; a variety of data sources to assess consistency and generalizability; a completely open approach including protocol, software, models, parameters, and raw results so that studies can be externally verified; and the study of many hypotheses in parallel so that the operating characteristics of the methods can be assessed.
RESULTS: OHDSI has already produced findings in areas like hypertension treatment that are being incorporated into practice, and it has produced rigorous studies of COVID-19 that have aided government agencies in their treatment decisions, that have characterized the disease extensively, that have estimated the comparative effects of treatments, and that the predict likelihood of advancing to serious complications.
CONCLUSIONS: OHDSI practices open science and incorporates a series of methods to address reproducibility. It has produced important results in several areas, including hypertension therapy and COVID-19 research. IMIA and Thieme. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Entities:  

Year:  2021        PMID: 33882595     DOI: 10.1055/s-0041-1726481

Source DB:  PubMed          Journal:  Yearb Med Inform        ISSN: 0943-4747


  4 in total

1.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.

Authors:  Xintong Li; Anna Ostropolets; Rupa Makadia; Azza Shoaibi; Gowtham Rao; Anthony G Sena; Eugenia Martinez-Hernandez; Antonella Delmestri; Katia Verhamme; Peter R Rijnbeek; Talita Duarte-Salles; Marc A Suchard; Patrick B Ryan; George Hripcsak; Daniel Prieto-Alhambra
Journal:  BMJ       Date:  2021-06-14

Review 2.  Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.

Authors:  Carla Epps; Ralph Bax; Alysha Croker; Dionna Green; Andrea Gropman; Agnes V Klein; Hannah Landry; Anne Pariser; Marc Rosenman; Michiyo Sakiyama; Junko Sato; Kuntal Sen; Monique Stone; Fumi Takeuchi; Jonathan M Davis
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

Review 3.  Electronic Health Record Network Research in Infectious Diseases.

Authors:  Ravi Jhaveri; Jordan John; Marc Rosenman
Journal:  Clin Ther       Date:  2021-10-08       Impact factor: 3.393

4.  Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.

Authors:  Xintong Li; Berta Raventós; Elena Roel; Andrea Pistillo; Eugenia Martinez-Hernandez; Antonella Delmestri; Carlen Reyes; Victoria Strauss; Daniel Prieto-Alhambra; Edward Burn; Talita Duarte-Salles
Journal:  BMJ       Date:  2022-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.